Back to all studies
🩸
Phase 2
Cholesterol
in-person
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
Sponsored by Eli Lilly and Company
Compensation
$500–$2,500
Duration
3 months
Location
Nationwide
About this study
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
Who can participate
- • Adults aged 18–99
- • All genders welcome
- • Diagnosed with or experiencing severe hypertriglyceridemia
- • Able to attend in-person clinic visits
What's included
- • Compensation up to $2,500
- • All study-related medical care at no cost
- • Lab work, screenings, and physician consultations
- • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.
Ready to Find a Paid Study?
Join over 100,000 people who have been matched with clinical studies. It's free, fast, and could change your life.